Belgian Metals and Mining Stock News

ENXTBR:BEKB
ENXTBR:BEKBMetals and Mining

A Look At Bekaert’s (ENXTBR:BEKB) Valuation After Dividend Increase Leadership Change And Q1 Update

Dividend decision and leadership changes set the tone for NV Bekaert NV Bekaert (ENXTBR:BEKB) has just wrapped up an eventful May, with shareholders approving a gross dividend of €1.95 per share alongside director reappointments, while the company confirmed Q1 2026 sales in line with expectations. See our latest analysis for NV Bekaert. Following the annual meeting, Q1 sales update, recent acquisitions in Thailand and China, and the appointment of a new CEO, the stock’s 1-day share price...
ENXTBR:KBC
ENXTBR:KBCBanks

KBC Group (ENXTBR:KBC) Margin Compression Challenges Bullish Earnings Narratives After Q1 2026 Results

KBC Group (ENXTBR:KBC) has opened 2026 with Q1 revenue of €3.1b and basic EPS of €1.32, setting the tone against a trailing twelve month backdrop of €12.1b in revenue and basic EPS of €8.67. Over recent quarters the company has seen revenue move from €2.6b in Q1 2025 to around €3.1b in Q1 2026, with basic EPS over that period ranging from about €1.28 to €2.50. This gives investors a clear view of how the top and bottom line are tracking into the new year. Taken together with a 28.6% net...
ENXTBR:PROX
ENXTBR:PROXTelecom

Will Weaker Q1 2026 Earnings Momentum Change Proximus' (ENXTBR:PROX) Investment Narrative?

Proximus PLC has reported past first-quarter 2026 results showing sales of €1,510 million and revenue of €1,525 million, with net income of €124 million and basic earnings per share from continuing operations of €0.38, all lower than the same period a year earlier. This broad-based decline across sales, revenue and earnings measures raises questions about how effectively Proximus’s existing efficiency programs and investment plans are offsetting current pressures on its business. We’ll now...
ENXTBR:AZE
ENXTBR:AZETrade Distributors

A Look At Azelis Group (ENXTBR:AZE) Valuation After Recent Share Price Rebound And Acquisition Activity

Recent performance and context for Azelis Group Azelis Group (ENXTBR:AZE) has drawn investor attention after a mixed stretch for the stock, with a decline over the past week but gains over the past month and past 3 months. Over the past 7 days the stock fell 2.04%, while the month period shows a 13.34% gain and the past 3 months are up 8.62%. Year to date, the stock is up 13.28%, although the 1 year total return is down 27.88% and the 3 year total return is down 47.76%. See our latest...
ENXTBR:VGP
ENXTBR:VGPReal Estate

Assessing VGP (ENXTBR:VGP) Valuation After Recent Share Price Weakness

Recent share performance and business context VGP (ENXTBR:VGP) has drawn investor attention after the stock declined 10.2% over the past day, extending falls of 5.6% over the past week and 11.3% over the past month. Those moves come as the €2.21b logistics and semi industrial real estate company, headquartered in Antwerp, continues to generate revenue of €191.99m and net income of €290.44m. This performance is partly supported by its renewable energy activities. See our latest analysis for...
ENXTBR:SOF
ENXTBR:SOFDiversified Financial

Assessing Sofina Société Anonyme (ENXTBR:SOF) Valuation After Recent Share Price Weakness

Short term moves put Sofina Société Anonyme (ENXTBR:SOF) under the spotlight Sofina Société Anonyme (ENXTBR:SOF) has drawn attention after its stock fell 1.1% in the latest session and is now down about 2.3% over the past month and 12.5% over the past 3 months. With a market value of about €7.7b and a last close of €218.40, the company offers exposure to a broad mix of private equity and venture capital holdings spanning digital transformation, healthcare, education, consumer sectors and...
ENXTBR:VIO
ENXTBR:VIOMetals and Mining

Assessing Viohalco (ENXTBR:VIO) Valuation After Investor Interest In Its Diversified Metals And Cables Operations

Viohalco (ENXTBR:VIO) drew attention after its stock climbed 13.55% in after-hours trading on EURONEXT on 7 May, as investors focused on its aluminium, copper, cables, and steel operations. See our latest analysis for Viohalco. That after hours jump adds to strong recent momentum, with a 7 day share price return of 16.45% and a 30 day share price return of 23.60%. The 1 year total shareholder return of 218.26% and 5 year total shareholder return of 288.09% underline how sentiment has shifted...
ENXTBR:CMBT
ENXTBR:CMBTOil and Gas

Assessing Cmb.Tech (ENXTBR:CMBT) Valuation After Strong Recent Share Price Momentum

Stock move puts Cmb.Tech (ENXTBR:CMBT) in focus Cmb.Tech (ENXTBR:CMBT) has drawn fresh attention after recent price action, with the stock last closing at €12.74. The company operates a business that spans marine transportation and hydrogen focused activities. See our latest analysis for Cmb.Tech. The recent 2.08% 1 day share price return and 15.19% 30 day share price return suggest positive momentum is building. The 57.77% 1 year total shareholder return and 166.44% 5 year total shareholder...
ENXTBR:ARGX
ENXTBR:ARGXBiotechs

Assessing argenx (ENXTBR:ARGX) Valuation After FDA Expansion Of Vyvgart Myasthenia Gravis Label

argenx (ENXTBR:ARGX) is back on investor radars after the FDA expanded the labels for Vyvgart and Vyvgart Hytrulo to cover all serotypes of adult generalized myasthenia gravis, significantly widening eligible patient coverage. See our latest analysis for argenx. The FDA label expansion lands after a busy stretch for argenx, including strong Q1 2026 results with higher Vyvgart sales, a CEO transition to Karen Massey, and a 1 year total shareholder return of 35.24%. However, the year to date...
ENXTBR:KBCA
ENXTBR:KBCABanks

Assessing KBC Ancora (ENXTBR:KBCA) Valuation After Recent Mixed Share Price Performance

Recent returns and what they might mean for investors KBC Ancora (ENXTBR:KBCA) has quietly posted mixed share price moves, with a 0.6% decline over the past day, a 2.2% gain over the past week, and around 4.5% over the past month. For longer term holders, the stock shows a modest gain of about 0.3% over the past 3 months, alongside a year to date return of roughly 5.4% and a 1 year total return close to 38.3%. See our latest analysis for KBC Ancora. With the share price at €79.4, KBC Ancora...
ENXTBR:MELE
ENXTBR:MELESemiconductor

Is Melexis' (ENXTBR:MELE) 17% Margin Guidance Reinforcing or Recasting Its Profitability Narrative?

In April 2026, Melexis NV reported first quarter sales of €202.09 million, modestly above a year earlier, while net income eased to €23.09 million and basic EPS from continuing operations slipped to €0.57. At the same time, the company confirmed its 2026 guidance, expecting first half sales to be broadly unchanged year over year with an operating margin around 17% and indicating that second half sales should exceed the first half. We’ll now examine how Melexis’ confirmed first half operating...
ENXTBR:SOLB
ENXTBR:SOLBChemicals

A Look At Solvay’s (ENXTBR:SOLB) Valuation After Recent Share Price Weakness

Solvay stock moves after recent performance data Solvay (ENXTBR:SOLB) has come into focus after a period in which the stock showed negative returns over the past month and past 3 months, prompting closer attention to its fundamentals and profitability profile. See our latest analysis for Solvay. At a share price of €26.28, Solvay’s recent 7 day share price return of a 5.81% decline adds to a year to date share price return of a 3.88% decline, contrasting with a 42.41% three year total...
ENXTBR:ARGX
ENXTBR:ARGXBiotechs

Argenx Leadership Shift And Vyvgart Milestones Reshape Autoimmune Growth Story

argenx (ENXTBR:ARGX) appointed Karen Massey as CEO, and co founder Tim Van Hauwermeiren moved to Chairperson. The company reported strong Q1 results, with accelerating VYVGART sales highlighted as a key driver. An FDA decision on a potential Vyvgart label expansion in seronegative generalized myasthenia gravis is expected soon. argenx focuses on antibody based therapies for autoimmune diseases, with VYVGART already a central product in its portfolio. For investors watching the immunology...
ENXTBR:MELE
ENXTBR:MELESemiconductor

Melexis (ENXTBR:MELE) Valuation After Q1 Results And 2026 Guidance Confirmation

What the latest guidance and results mean for Melexis (ENXTBR:MELE) Melexis (ENXTBR:MELE) shares have been reacting to the company confirming its 2026 guidance alongside Q1 results, with sales at €202.09 million and net income at €23.09 million, compared with €24.6 million a year earlier. See our latest analysis for Melexis. The confirmation of 2026 guidance alongside Q1 results appears to have shifted sentiment, with the stock’s 30 day share price return of 39.34% and 1 year total...
ENXTBR:ABI
ENXTBR:ABIBeverage

Anheuser-Busch InBev Cannes Hat-Trick And What It Means For Valuation

Anheuser-Busch InBev (ENXTBR:ABI) has been named the 2026 Creative Marketer of the Year by the Cannes Lions International Festival of Creativity. This is the first time any company has received the award three times. The recognition follows the company winning 37 Lions at last year's festival. Anheuser-Busch InBev, the global brewer behind brands across beer and beyond, is being recognized for how it uses marketing and creativity across its portfolio. For investors, this award signals that...
ENXTBR:SYENS
ENXTBR:SYENSChemicals

Syensqo Share Cancellation Reshapes Ownership As Valuation Gap Persists

Syensqo cancelled a significant number of shares it had repurchased as part of its ongoing buyback program. The move changes the total number of outstanding shares and voting rights for ENXTBR:SYENS. The action forms part of a broader capital management approach that affects how ownership is distributed across shareholders. For investors watching ENXTBR:SYENS, the cancellation of repurchased shares directly alters the share count that sits behind the current €57.3 price. Recent performance...
ENXTBR:UMI
ENXTBR:UMIChemicals

Is It Too Late To Reassess Umicore (ENXTBR:UMI) After Its 167% One-Year Rally?

If you are wondering whether Umicore’s recent share price movement makes the stock look expensive or if there is still value available, this article breaks down what the current price might be implying. The share price closed at €21.82, with returns of 27.0% over 7 days, 23.6% over 30 days, 17.4% year to date, 167.3% over 1 year, a 17.3% decline over 3 years, and a 51.2% decline over 5 years. This gives you a mixed picture depending on your time frame. Recent coverage has focused on...
ENXTBR:ARGX
ENXTBR:ARGXBiotechs

Argenx (ENXTBR:ARGX) Margin Compression In Q1 2026 Tests Bullish Growth Narrative

argenx (ENXTBR:ARGX) has opened 2026 with Q1 revenue of about US$1.3b and basic EPS of US$5.90. On a trailing 12 month basis the company has generated US$4.7b of revenue and basic EPS of US$24.19. This sets a clear earnings backdrop for investors watching the stock around its current US$671.20 share price. Over recent quarters the company has seen revenue move from US$807.37m in Q1 2025 to roughly US$1.3b in Q1 2026, with quarterly basic EPS ranging between US$2.78 and US$12.79 across that...
ENXTBR:SOLB
ENXTBR:SOLBChemicals

Solvay (ENXTBR:SOLB) Q1 Profit Of €26 Million Tests Loss-Making Narrative

Solvay (ENXTBR:SOLB) opened 2026 with Q1 revenue of €1.1 billion and basic EPS of €0.25, alongside trailing twelve month revenue of €4.6 billion and a basic EPS loss of €0.24, setting a mixed backdrop for the latest results. Over recent quarters the company has seen revenue range between €1.1 billion and €1.3 billion per quarter, with basic EPS moving from €0.78 in Q1 2025 through several smaller profits and a loss of €0.90 in Q4 2025 before rebounding in Q1 2026, leaving investors focused on...